Clinical Observations on the Association Between Diagnosis of Lung Cancer and Serum Tumor Markers in Combination

  • Wang, Wen-Jing (Department of Infectious Diseases, Nanjing First Hospital, Nanjing Medical University) ;
  • Tao, Zhen (Department of Infectious Diseases, Nanjing First Hospital, Nanjing Medical University) ;
  • Gu, Wei (Department of Respiration, Nanjing First Hospital, Nanjing Medical University) ;
  • Sun, Li-Hua (Department of Respiration, Nanjing First Hospital, Nanjing Medical University)
  • Published : 2013.07.30


Objective: To evaluate the association of a diagnosis of lung cancer and combined detection of serum carcinoembryonic antigen (CEA), carbohydrateantigen 19-9 (CA19-9), neuron specific enolase (NSE) as well as the cytokeratin 19 fragment (CYFRA21-1). Methods: Serum CEA, CA19-9, NSE and CYFRA21-1 were assessed in 150 patients with lung cancer, 100 patients with benign lung disease and 100 normal control subjects, and differences of expression were compared in each group, and joint effects of these tumor markers in the diagnosis of lung cancer were analyzed. Results: Serum CEA, CA19-9, NSE and CYFRA21-1 in patients with lung cancer were significantly higher than those with benign lung disease and normal controls (p<0.01). It is suggested that these four tumor markers combined together could produce a positive detection rate of 90.2%, significantly higher than that of any single test. Conclusion: Combination detection of CEA, CA19-9, NSE and CYFRA21-1 could significantly improve the sensitivity and specificity in diagnosis of lung cancer, and could be important in early detection.


Lung cancer;CEA;CA199;NSE;CYFRA21-1


  1. Ardizzoni A, Cafferate MA, Tiseo M, et al (2006). Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer, 107, 2842-9.
  2. Bilgin E, Dizdar Y, Serilmez M, et al (2013). For which cancer types can neuron-specific enolase be clinically helpful in Turkish patients? Asian Pac J Cancer Prev, 14, 2541-4.
  3. Buccheri G, Eerrigno D (2002). Lung tumor markers in oncology practice: a study of TPA and CA125. Br J Cancer, 87, 1112-8.
  4. Cho JY, Sung HJ (2009). Proteomic approaches in lung cancer biomarker development. Expert Rev Proteomics, 6, 27-42.
  5. Fletcher CD, Berman JJ, Corless C, et al (2002). Diagnosis of gastrointestinal stromal tumoes: a consensus approach. Hum Patnol, 33, 459-65.
  6. Hu LA, Fu Y, Zhang DN, et al (2013). Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2563-6.
  7. Kav S, Tokdemir G, Tasdemir R, et al (2012). Patients with cancer and their relatives beliefs, information needs and information-seeking behavior about cancer and treatment. Asian Pac J Cancer Prev, 13, 6027-32.
  8. Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with Stage III non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5.
  9. Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8.
  10. Malik PS, Sharma MC, Mohanti BK, et al (2013). Clinicopathological profile of lung cancer at AIIMS: a changing paradigm in India. Asian Pac J Cancer Prev, 14, 489-94.
  11. Oguz A, Unal D, Tasdemir A, et al (2013). Lack of any association between blood groups and lung cancer, independent of histology. Asian Pac J Cancer Prev, 14, 453-6.
  12. Pan JB, Hou YH, Zhang GJ (2013). Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients. Asian Pac J Cancer Prev, 14, 695-700.
  13. Parkin DM, Brary FB, Pisani P (2005). Global cancer statistics. Cancer J Clin, 55, 74-108.
  14. Ramshankar V, Krishnamurthy A (2013). Lung cancer detection by screening - presenting circulating miRNAs as a promising next generation biomarker breakthrough. Asian Pac J Cancer Prev, 14, 2167-72.
  15. Schneider J, Bitterlich N, Velcovsky HG, et al (2002). Fuzzy logic based tumor marker profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol, 7, 145-51.

Cited by

  1. Clinical Significance of Combined Detection of Serum Tumor Markers in Diagnosis of Patients with Ovarian Cancer vol.14, pp.11, 2013,
  2. Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer vol.14, pp.8, 2013,
  3. Prediction of Lung Cancer Based on Serum Biomarkers by Gene Expression Programming Methods vol.15, pp.21, 2014,
  4. Follistatin Is a Novel Biomarker for Lung Adenocarcinoma in Humans vol.9, pp.10, 2014,
  5. Comparative Assessment of the Diagnostic Value of Transbronchial Lung Biopsy and Bronchoalveolar Lavage Fluid Cytology in Lung Cancer vol.16, pp.1, 2015,
  6. Correlation between Serum Carcinoembryonic Antigen Level and Histologic Subtype in Resected Lung Adenocarcinoma vol.16, pp.9, 2015,
  7. Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China vol.3, pp.4, 2015,
  8. High Performance, Multiplexed Lung Cancer Biomarker Detection on a Plasmonic Gold Chip vol.26, pp.44, 2016,
  9. Monitoring with sensitive tumor markers contributes to decision-making and better prognosis in gastric cancer patients with peritoneal recurrence vol.22, pp.5, 2017,
  10. Clinical Evaluation and Therapeutic Monitoring Value of Serum Tumor Markers in Lung Cancer vol.31, pp.1, 2016,
  11. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible? vol.2018, pp.1875-8630, 2018,